School, college and other closings for Monday

MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible to all. 

Turn Up Your Support

The new omicron strain of COVID-19 first discovered in South Africa was declared a variant of concern by the World Health Organization on Friday. Here's how the pharmaceutical industry plans to address the latest coronavirus curve ball. 

Vaccine makers are already pivoting their efforts to combat the new variant: testing higher doses of booster shots, designing new boosters that anticipate strain mutations, and developing omicron-specific boosters.

In a statement sent to NPR, Moderna said it has been working on a comprehensive strategy to predict variants of concern since the beginning of 2021. One approach is to double the current booster from 50 to 100 micrograms. Secondly, the vaccine maker has been studying two

booster vaccines that are designed to anticipate mutations like those found in the omicron variant. The company also said it will ramp up efforts to make a booster candidate that specifically targets omicron.

"From the beginning, we have said that as we seek to defeat the pandemic, it is imperative that we are proactive as the virus evolves," said Moderna CEO Stéphane Bancel. "The mutations in the omicron variant are concerning and for several days, we have been moving as fast as possible to execute our strategy to address this variant."

 that they expect more data about the omicron variant to be collected within two weeks. That information will help determine whether or not they need to modify their current vaccine. Pfizer and BioNTech said that a vaccine tailored for the omicron variant, if needed, could be ready to ship in about 100 days. 

Johnson & Johnson said in a statement sent to NPR that it, too, is already testing its vaccine's efficacy against the new variant.

first reported to the WHO on Nov. 24, the agency said. Preliminary evidence indicates the variant poses an increased risk for reinfection due to the large number of mutations. Until recently, cases across South Africa had predominantly been from the delta variant, an earlier strain that has pushed health care systems to the max since early summer. But omicron infections have been on the rise in recent weeks, 

News of the rapidly spreading variant led to a new set of air travel restrictions from South Africa and seven other countries, implemented by President Joe Biden, that go into effect Monday. The president made the announcement the day after Thanksgiving, one of the busiest travel periods of the year. 

millions of people traveled against the advice of health experts

, the Centers for Disease Control and Prevention and chief medical advisor to the president, 

, more or less condoned Thanksgiving get-togethers for vaccinated Americans. And, according to an 

 travel forecast, more than 53 million people were expected to travel for Thanksgiving —  an 18 percent jump compared to last year — including more than 4 million by air.

As of Sunday morning, officials had not reported any cases of the omicron variant in the United States. However, Fauci said on Saturday that he would not be surprised if the variant is already here.

"We have not detected it yet, but when you have a virus that is showing this degree of transmissibility and you're already having travel-related cases that they've noted in Israel and Belgium and other places ... it almost invariably is ultimately going to go essentially all over," he 

said in an interview on NBC’s Today show

As Americans prepare to transition from one busy holiday to the next, the 

 that coronavirus cases, hospitalizations and deaths will increase over the next four weeks. More than 776,000 people in the U.S. have died of COVID-19 to date, 

according to Johns Hopkins University's tracker

 to surpass 800,000 deaths by Christmas.   

Science

Health

COVID-19

Dustin Jones

Author

Vaccine makers are already pivoting their efforts to combat new coronavirus variants: testing higher doses of booster shots, designing new boosters that anticipate strain mutations, and developing omicron-specific boosters.

How vaccine makers plan to address the new omicron coronavirus variant

Go Deeper.

Like this?

News you can use in your inbox